SAKK 06/19, NCT04630730: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC |
|
|
| Recruiting | 2 | 46 | Europe | Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), VPM1002BC, Atezolizumab, Tecentriq™, Cisplatin, Platinol®, Gemcitabine, Gemzar ® | Swiss Group for Clinical Cancer Research | Bladder Cancer | 06/26 | 06/30 | | |
| Completed | 1/2 | 39 | Europe | VPM1002BC, Mycobacterium bovis BCG∆ureC::Hly+, VPM1002 | Swiss Group for Clinical Cancer Research | Bladder Cancer | 10/19 | 03/23 | | |
NCT05539989: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa |
|
|
| Withdrawn | 1/2 | 480 | RoW | VPM1002 Vaccine, BCG Vaccine, Placebo | International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH) | Tuberculosis, HIV Infections | 07/27 | 07/27 | | |
